Skip to main navigation Skip to search Skip to main content

Novel parkin mutations detected in patients with early-onset Parkinson's disease

  • A.M. Bertoli-Avella
  • , J.L. Giroud-Benitez
  • , A. Akyol
  • , E. Barbosa
  • , O. Schaap
  • , H.C. van der Linde
  • , E. Martignoni
  • , L. Lopiano
  • , P. Lamberti
  • , E. Fincati
  • , A. Antonini
  • , F. Stocchi
  • , P. Montagna
  • , F. Squitieri
  • , P. Marini
  • , G. Abbruzzese
  • , G. Fabbrini
  • , R. Marconi
  • , A. Dalla Libera
  • , G. Trianni
  • M. Guidi, A. de Gaetano, G. Boff Maegawa, A. de Leo, V. Gallai, G. de Rosa, N. Vanacore, G. Meco, C.M. van Duijn, B.A. Oostra, P. Heutink, V. Bonifati

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

A multiethnic series of patients with early-onset Parkinson's disease (EOP) was studied to assess the frequency and nature of parkin/PARK2 gene mutations and to investigate phenotype-genotype relationships. Forty-six EOP probands with an onset age of <45 years, and 14 affected relatives were ascertained from Italy, Brazil, Cuba, and Turkey. The genetic screening included direct sequencing and exon dosage using a new, cost-effective, real-time polymerase chain reaction method. Mutations were found in 33% of the indexes overall, and in 53% of those with family history compatible with autosomal recessive inheritance. Fifteen parkin alterations (10 exon deletions and five point mutations) were identified, including four novel mutations: Arg402Cys, Cys418Arg, IVS113C>G, and exon 8-9-10 deletion. Homozygous mutations, two heterozygous mutations, and a single heterozygous mutation were found in 8, 6, and 1 patient, respectively. Heterozygous exon deletions represented 28% of the mutant alleles. The patients with parkin mutations showed significantly earlier onset, longer disease duration, more frequently symmetric onset, and slower disease progression than the patients without mutations, in agreement with previous studies. This study confirms the frequent involvement of parkin and the importance of genetic testing in the diagnostic work-up of EOP. © 2004 Movement Disorder Society.
Original languageEnglish
Pages (from-to)424-431
JournalMovement Disorders
Volume20
Issue number4
DOIs
Publication statusPublished - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Novel parkin mutations detected in patients with early-onset Parkinson's disease'. Together they form a unique fingerprint.

Cite this